Compare EVO & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | KBDC |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | EVO | KBDC |
|---|---|---|
| Price | $3.67 | $14.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $15.80 |
| AVG Volume (30 Days) | 68.7K | ★ 304.9K |
| Earning Date | 11-05-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 13.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $887,396,457.00 | N/A |
| Revenue This Year | N/A | $193.84 |
| Revenue Next Year | $8.52 | $9.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.84 | $13.06 |
| 52 Week High | $4.80 | $17.99 |
| Indicator | EVO | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 40.50 |
| Support Level | $3.53 | $14.14 |
| Resistance Level | $3.81 | $14.63 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 54.17 | 12.07 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.